{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:23:49Z","timestamp":1777519429501,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.vaccine.2024.06.041","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T13:29:08Z","timestamp":1719581348000},"page":"126074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9553-4340","authenticated-orcid":false,"given":"Sita","family":"Bhella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6677-5293","authenticated-orcid":false,"given":"Allison M.","family":"Wilkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrina","family":"Hueniken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5369-1501","authenticated-orcid":false,"given":"Abi","family":"Vijenthira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9013-2941","authenticated-orcid":false,"given":"Michael","family":"Sebag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa K.","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4581-3390","authenticated-orcid":false,"given":"Annette E.","family":"Hay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarit","family":"Assouline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graeme","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2831-9107","authenticated-orcid":false,"given":"Amaris","family":"Balitsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1364-5030","authenticated-orcid":false,"given":"Joy","family":"Mangel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Owen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Reiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie","family":"Sehn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8872-1934","authenticated-orcid":false,"given":"Heather","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2108-6301","authenticated-orcid":false,"given":"Tinghua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1431-8958","authenticated-orcid":false,"given":"Tamara","family":"Leite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erinn","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3368-3499","authenticated-orcid":false,"given":"Curtis","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc-Andre","family":"Langlois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Arianne Buchan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.06.041_b0005","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2024.06.041_b0010","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S1473-3099(18)30600-5","article-title":"Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Cordonnier","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.06.041_b0015","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1016\/S1473-3099(18)30601-7","article-title":"Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Mikulska","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.06.041_b0020","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.06.041_b0025","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.06.041_b0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.06.041_b0035","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim Results of a Phase 1\u20132a Trial of Ad26.COV2.S Covid-19 Vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.06.041_b0040","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3324\/haematol.2021.279216","article-title":"Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies","volume":"107","author":"Gurion","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.vaccine.2024.06.041_b0045","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/bloodadvances.2021005094","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma","volume":"5","author":"Perry","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.vaccine.2024.06.041_b0050","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ccell.2021.06.014","article-title":"Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma","author":"Van Oekelen","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.vaccine.2024.06.041_b0055","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/bjh.17918","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients","volume":"196","author":"Shem-Tov","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.vaccine.2024.06.041_b0060","first-page":"12","article-title":"Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial","author":"Thakkar","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.vaccine.2024.06.041_b0065","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/bjh.18073","article-title":"Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres","volume":"197","author":"\u0160u\u0161ol","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.vaccine.2024.06.041_b0070","doi-asserted-by":"crossref","first-page":"e2251833","DOI":"10.1001\/jamanetworkopen.2022.51833","article-title":"Analysis of mRNA COVID-19 vaccine uptake among immunocompromised individuals in a large US health system","volume":"6","author":"Tartof","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2024.06.041_b0075","first-page":"11","article-title":"Serological response to three, four and five doses of SARS-CoV-2 vaccine in kidney transplant recipients","author":"Osmanodja","year":"2022","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.vaccine.2024.06.041_b0080","first-page":"52","article-title":"Effectiveness of successive booster vaccine doses against SARS-CoV-2 related mortality in residents of long-term care facilities in the VIVALDI study","author":"Stirrup","year":"2023","journal-title":"Age Ageing"},{"issue":"706","key":"10.1016\/j.vaccine.2024.06.041_b0085","first-page":"e1","article-title":"Immunogenicity and safety of booster SARS-CoV-2 mRNA vaccine dose in allogeneic hematopoietic stem cell transplantation recipients","volume":"29","author":"Mittal","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.vaccine.2024.06.041_b0090","doi-asserted-by":"crossref","first-page":"e075286","DOI":"10.1136\/bmj-2022-075286","article-title":"Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged \u226550 years in Nordic countries: nationwide cohort study","volume":"382","author":"Andersson","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2024.06.041_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102040","article-title":"Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study","volume":"61","author":"Hofsink","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2024.06.041_b0100","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41591-020-0913-5","article-title":"A serological assay to detect SARS-CoV-2 seroconversion in humans","volume":"26","author":"Amanat","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2024.06.041_b0105","doi-asserted-by":"crossref","first-page":"e1380","DOI":"10.1002\/cti2.1380","article-title":"A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination","volume":"11","author":"Colwill","year":"2022","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.vaccine.2024.06.041_b0110","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jgo.2021.12.017","article-title":"Overview of Sankey flow diagrams: focusing on symptom trajectories in older adults with advanced cancer","volume":"13","author":"Otto","year":"2022","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.vaccine.2024.06.041_b0115","doi-asserted-by":"crossref","unstructured":"Ripley BD, Others. The R project in statistical computing. MSOR Connections The newsletter of the LTSN Maths, Stats & OR Network. 2001;1: 23\u201325.","DOI":"10.11120\/msor.2001.01010023"},{"key":"10.1016\/j.vaccine.2024.06.041_b0120","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.2021012443","article-title":"Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies","volume":"138","author":"Ghione","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2024.06.041_b0125","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/s43018-021-00275-9","article-title":"Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study","volume":"2","author":"Fendler","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.vaccine.2024.06.041_b0130","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","article-title":"Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study","volume":"8","author":"Maneikis","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.vaccine.2024.06.041_b0135","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1136\/ard-2022-222579","article-title":"Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study","volume":"81","author":"Mrak","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2024.06.041_b0140","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1016\/S2665-9913(23)00160-1","article-title":"Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY","volume":"5","author":"Pearce","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.vaccine.2024.06.041_b0145","first-page":"11","article-title":"Prevalence and motivators of getting a COVID-19 booster vaccine in canada: results from the iCARE study","author":"L\u00e9ger","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2024.06.041_b0150","unstructured":"Public Health Agency of Canada. Guidance on an additional dose of COVID-19 vaccines in the spring for individuals at high risk of severe illness due to COVID-19. 12 Jan 2024 [cited 29 Feb 2024]. Available: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/vaccines-immunization\/national-advisory-committee-immunization-guidance-additional-dose-covid-19-vaccines-spring-2024-individuals-high-risk-severe-illness-due-covid-19.html."},{"key":"10.1016\/j.vaccine.2024.06.041_b0155","unstructured":"Case Definitions. In: Brighton Collaboration [Internet]. 19 Apr 2023 [cited 29 Feb 2024]. Available: https:\/\/brightoncollaboration.org\/case-definitions-table-view\/."},{"issue":"4","key":"10.1016\/j.vaccine.2024.06.041_b0160","doi-asserted-by":"crossref","first-page":"E132","DOI":"10.1002\/ajh.26459","article-title":"COVID-19 vaccine response in patients with hematologic malignancy: a systematic review and meta-analysis","volume":"97","author":"Gong","year":"2022","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.vaccine.2024.06.041_b0165","doi-asserted-by":"crossref","first-page":"e062187","DOI":"10.1136\/bmjopen-2022-062187","article-title":"Cohort profile: Stop the Spread Ottawa (SSO) \u2013 a community-based prospective cohort study on antibody responses, antibody neutralization efficiency and cellular immunity to SARS-CoV-2 infection and vaccination","volume":"12","author":"Collins","year":"2022","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.vaccine.2024.06.041_b0170","doi-asserted-by":"crossref","first-page":"e077714","DOI":"10.1136\/bmjopen-2023-077714","article-title":"Results of the Stop the Spread Ottawa (SSO) cohort study: a Canadian urban-based prospective evaluation of antibody responses and neutralization efficiency to SARS-CoV-2 infection and vaccination","volume":"13","author":"Keeshan","year":"2023","journal-title":"BMJ Open"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24007151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24007151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T17:47:49Z","timestamp":1729014469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24007151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":34,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0264410X24007151"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.06.041","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.06.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126074"}}